Eli Lilly and Company (LLY) Q3 2026 (USD): adj. EPS 7.48 (exp. 5.68), Revenue 24.4bln (exp. 22.58bln); Mounjaro 10.7bln, Zepbound 5.3bln. Current FY Rev. 91-92bln (exp. 88.82bln)

Eli Lilly and Company (LLY) Q3 2026 (USD): adj. EPS 7.48 (exp. 5.68), Revenue 24.4bln (exp. 22.58bln); Mounjaro 10.7bln, Zepbound 5.3bln. Current FY Rev. 91-92bln (exp. 88.82bln)

Beats of this size on both lines, paired with a guidance raise well above consensus, have been the established pattern for Lilly through the GLP-1 cycle, and the read-across has historically run beyond the single name to the obesity peer set and the contract manufacturing and supply chain names attached to it. The prior form in this franchise is that revenue is supply-constrained rather than demand-constrained, so the tell on the call is commentary on capacity additions and fill rates rather than prescription trends, which have consistently run ahead of what the company can ship. The split worth watching is Mounjaro versus Zepbound trajectory, since the diabetes and obesity labels price and reimburse differently and the margin mix shifts with the obesity share. Follow-ons that have mattered in past episodes of this kind are any update on the oral GLP-1 pipeline, competitor readouts that reset the efficacy bar, and reimbursement and pricing commentary, which is where the political pressure point on this class has sat. Guidance raises of this kind have tended to be conservative in retrospect for this issuer, but the sensitivity of the stock to the print has grown with the multiple, so the initial reaction size is less informative than whether the call sustains the raise narrative.